DK169128B1 - Thiazolderivater og farmaceutiske præparater med virkning som leukotrienantagonist indeholdende disse som aktiv bestanddel samt anvendelse af thiazolderivaterne til fremstilling af sådanne præparater - Google Patents

Thiazolderivater og farmaceutiske præparater med virkning som leukotrienantagonist indeholdende disse som aktiv bestanddel samt anvendelse af thiazolderivaterne til fremstilling af sådanne præparater Download PDF

Info

Publication number
DK169128B1
DK169128B1 DK494186A DK494186A DK169128B1 DK 169128 B1 DK169128 B1 DK 169128B1 DK 494186 A DK494186 A DK 494186A DK 494186 A DK494186 A DK 494186A DK 169128 B1 DK169128 B1 DK 169128B1
Authority
DK
Denmark
Prior art keywords
group
meanings
previously defined
carbon atoms
compound
Prior art date
Application number
DK494186A
Other languages
Danish (da)
English (en)
Other versions
DK494186D0 (da
DK494186A (da
Inventor
Yosio Hayasi
Tomei Oguri
Masaki Shinoda
Mikio Tsutsui
Kazuo Takahashi
Hitoshi Miida
Original Assignee
Mitsubishi Chem Ind
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Chem Ind filed Critical Mitsubishi Chem Ind
Publication of DK494186D0 publication Critical patent/DK494186D0/da
Publication of DK494186A publication Critical patent/DK494186A/da
Application granted granted Critical
Publication of DK169128B1 publication Critical patent/DK169128B1/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK494186A 1985-10-16 1986-10-15 Thiazolderivater og farmaceutiske præparater med virkning som leukotrienantagonist indeholdende disse som aktiv bestanddel samt anvendelse af thiazolderivaterne til fremstilling af sådanne præparater DK169128B1 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP22891285 1985-10-16
JP60228912A JPS62142168A (ja) 1985-10-16 1985-10-16 チアゾ−ル誘導体及びそれを有効成分とするロイコトリエンきつ抗剤

Publications (3)

Publication Number Publication Date
DK494186D0 DK494186D0 (da) 1986-10-15
DK494186A DK494186A (da) 1987-04-17
DK169128B1 true DK169128B1 (da) 1994-08-22

Family

ID=16883798

Family Applications (1)

Application Number Title Priority Date Filing Date
DK494186A DK169128B1 (da) 1985-10-16 1986-10-15 Thiazolderivater og farmaceutiske præparater med virkning som leukotrienantagonist indeholdende disse som aktiv bestanddel samt anvendelse af thiazolderivaterne til fremstilling af sådanne præparater

Country Status (11)

Country Link
US (1) US4902700A (esLanguage)
EP (1) EP0219436B1 (esLanguage)
JP (1) JPS62142168A (esLanguage)
KR (1) KR930006285B1 (esLanguage)
AU (1) AU603343B2 (esLanguage)
CA (1) CA1326034C (esLanguage)
DE (1) DE3689436T2 (esLanguage)
DK (1) DK169128B1 (esLanguage)
HU (1) HU203228B (esLanguage)
SU (1) SU1554763A3 (esLanguage)
UA (1) UA5585A1 (esLanguage)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5258395A (en) * 1984-11-12 1993-11-02 Yamanouchi Pharmaceutical Co., Ltd. Thiazole compounds as inhibitors of SRS-A
JPS63258854A (ja) * 1987-04-16 1988-10-26 Mitsubishi Kasei Corp カルボキシスチレン誘導体およびそれを有効成分とする薬剤
US4895953A (en) * 1987-09-30 1990-01-23 American Home Products Corporation 2-Aryl substituted heterocyclic compounds as antiallergic and antiinflammatory agents
US4826990A (en) * 1987-09-30 1989-05-02 American Home Products Corporation 2-aryl substituted heterocyclic compounds as antiallergic and antiinflammatory agents
US4957932A (en) * 1987-11-25 1990-09-18 Merck Frosst Canada, Inc. Benzoheterazoles
US4962117A (en) * 1987-11-25 1990-10-09 Merck Frosst Canada, Inc. Heterazole dialkanoic acids
US5037840A (en) * 1987-11-25 1991-08-06 Merck Frosst Canada, Inc. Benzothiazoles
EP0318085A3 (en) * 1987-11-25 1990-03-14 Merck Frosst Canada Inc. Heterazole dialkanoic acids
US5004743A (en) * 1987-11-25 1991-04-02 Merck Frosst Canada, Inc. Pyridyl styrene dialkanoic acids as anti-leukotriene agents
ZA894913B (en) * 1988-07-12 1990-03-28 Ici Pharma Heterocyclic compounds
ES2052825T3 (es) * 1988-07-15 1994-07-16 Hoffmann La Roche Derivados de cicloalquiltiazol.
US5001140A (en) * 1989-04-17 1991-03-19 Hoffmann-La Roche Inc. Cycloalkylthiazoles
US5045554A (en) * 1988-11-29 1991-09-03 Monsanto Company Substituted thiazoles and their use as fungicides
JPH02169584A (ja) * 1988-12-22 1990-06-29 Mitsubishi Kasei Corp ビニルチアゾール誘導体およびそれを有効成分とする薬剤
US5089495A (en) * 1989-01-30 1992-02-18 Imperial Chemical Industries Plc Heterocyclic thiazole derivatives and pharmaceutical compositions comprising said derivatives
WO1990011278A1 (fr) * 1989-03-24 1990-10-04 The Green Cross Corporation Composes de thiazole et leurs applications
JPH03173874A (ja) * 1989-09-29 1991-07-29 Mitsubishi Kasei Corp 新規複素環化合物
WO1992000963A1 (fr) * 1990-07-12 1992-01-23 Yoshitomi Pharmaceutical Industries, Ltd. Composes de styryle et leur utilisation comme medicaments
JP2832923B2 (ja) * 1990-07-13 1998-12-09 吉富製薬株式会社 スチリル化合物およびその医薬用途
JP2600644B2 (ja) * 1991-08-16 1997-04-16 藤沢薬品工業株式会社 チアゾリルベンゾフラン誘導体
UA43318C2 (uk) * 1992-02-05 2001-12-17 Берінгер Інгельхейм Кг Похідні амідину, фармацевтична композиція з антагоністичною по відношенню до лейкотриєну в4 активністю
CA2132722A1 (en) * 1992-04-10 1993-10-28 Robert Zamboni Benzothiazole-substituted benzyl alcohols as leukotriene antogonists
CA2132724A1 (en) * 1992-04-10 1993-10-28 Robert Zamboni Thiazole-substituted benzyl alcohols as leukotriene antagonists
DE4219765A1 (de) * 1992-06-17 1993-12-23 Bayer Ag Substituierte (Benzothiazolyl- und Chinoxalyl-methoxy)phenylessigsäurederivate
US5273986A (en) * 1992-07-02 1993-12-28 Hoffmann-La Roche Inc. Cycloalkylthiazoles
US5508408A (en) * 1993-09-10 1996-04-16 Ciba-Geigy Corporation Quinoline compound
JPH11506425A (ja) * 1995-04-21 1999-06-08 第一製薬株式会社 エチニルチアゾール誘導体
AU1110497A (en) * 1995-12-14 1997-07-03 Kaken Pharmaceutical Co., Ltd. Thiazole derivatives
US6376671B1 (en) 1997-06-17 2002-04-23 Kaken Pharmaceutical Co., Ltd. 2-sulfamoylbenzoic acid derivatives
KR100563430B1 (ko) * 1997-06-17 2006-03-22 가켄 세이야쿠 가부시키 가이샤 2-술파모일벤조산 유도체
JP2004137284A (ja) * 1997-06-17 2004-05-13 Kaken Pharmaceut Co Ltd ２−スルファモイル安息香酸誘導体
US6083966A (en) 1998-08-31 2000-07-04 University Of Florida Thiazoline acid derivatives
CN1585639A (zh) * 1998-09-21 2005-02-23 佛罗里达大学研究基金会 抗疟疾制剂
JP4815083B2 (ja) * 1999-08-31 2011-11-16 メルク・シャープ・エンド・ドーム・コーポレイション 複素環化合物およびそれの使用方法
EP1103180B1 (de) * 1999-11-25 2005-01-12 Ciba SC Holding AG Hydroxyphenylvinylthiazole
US6624182B1 (en) 1999-11-25 2003-09-23 Ciba Specialty Chemicals Corporation Hydroxyphenylvinylthiazoles
ES2327816T3 (es) * 2000-04-03 2009-11-04 Ihara Chemical Industry Co., Ltd. Procedimiento para la preparacion de esteres de acido amico.
WO2002087589A1 (en) * 2001-04-26 2002-11-07 Daiichi Pharmaceutical Co., Ltd. Medicine for inhibiting drug elimination pump
US7056917B2 (en) 2001-04-26 2006-06-06 Daiichi Pharmaceutical Co., Ltd. Drug efflux pump inhibitor
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
GB0226930D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
BRPI0410348A (pt) 2003-05-14 2006-05-30 Torreypines Therapeutics Inc compostos e usos dos mesmos na modulação de amilóide-beta
AU2003270473A1 (en) * 2003-09-09 2005-04-27 University Of Florida Desferrithiocin derivatives and their use as iron chelators
PE20060315A1 (es) * 2004-05-24 2006-05-15 Irm Llc Compuestos de tiazol como moduladores de ppar
TW200600086A (en) 2004-06-05 2006-01-01 Astrazeneca Ab Chemical compound
BRPI0516595A (pt) 2004-10-16 2008-09-23 Astrazeneca Ab processo para fabricar um composto, e, composto
BRPI0610644B8 (pt) * 2005-04-04 2021-05-25 Univ Florida composto e composição farmacêutica que compreende tal composto e um veículo ou diluente farmaceuticamente aceitável.
TW200714597A (en) 2005-05-27 2007-04-16 Astrazeneca Ab Chemical compounds
ES2397648T3 (es) 2005-07-09 2013-03-08 Astrazeneca Ab Derivados de heteroarilbenzamida para uso como activadores de GLK en el tratamiento de la diabetes
TW200738621A (en) 2005-11-28 2007-10-16 Astrazeneca Ab Chemical process
JP4836704B2 (ja) * 2006-08-07 2011-12-14 中国電力株式会社 端子台用保護カバー
TW200825063A (en) 2006-10-23 2008-06-16 Astrazeneca Ab Chemical compounds
TW200825060A (en) 2006-10-26 2008-06-16 Astrazeneca Ab Chemical compounds
TW200833339A (en) 2006-12-21 2008-08-16 Astrazeneca Ab Novel crystalline compound
NZ579994A (en) 2007-03-15 2011-09-30 Univ Florida Desferrithiocin polyether analogues useful in the treatment of pathological conditions responsive to chelation or sequestration of trivalent metal
CA2732165A1 (en) 2008-08-04 2010-02-11 Astrazeneca Ab Therapeutic agents 414
EP2166006A1 (en) * 2008-09-18 2010-03-24 Dompe' S.P.A. 2-aryl-propionic acids and derivatives and pharmaceutical compositions containing them
GB0902434D0 (en) 2009-02-13 2009-04-01 Astrazeneca Ab Chemical process
GB0902406D0 (en) 2009-02-13 2009-04-01 Astrazeneca Ab Crystalline polymorphic form
WO2010116177A1 (en) 2009-04-09 2010-10-14 Astrazeneca Ab A pyrazolo [4,5-e] pyrimidine derivative and its use to treat diabetes and obesity
AR076221A1 (es) * 2009-04-09 2011-05-26 Astrazeneca Ab Derivado de pirazol [4,5-e] pirimidina y su uso para tratar diabetes y obesidad
JP6012468B2 (ja) 2009-10-02 2016-10-25 アヴェクシン エーエス 抗炎症性２−オキソチアゾールおよび２−オキソオキサゾール
EP2790697B1 (en) 2011-12-16 2019-10-23 University of Florida Research Foundation, Inc. Uses of 4'-desferrithiocin analogs
CN110128370A (zh) 2013-01-29 2019-08-16 埃维克辛公司 抗炎症和抗肿瘤的2-氧代噻唑类和2-氧代噻吩类化合物
WO2015077655A1 (en) 2013-11-22 2015-05-28 University Of Florida Research Foundation, Inc. Desferrithiocin analogs and uses thereof
GB201413695D0 (en) 2014-08-01 2014-09-17 Avexxin As Compound
WO2016176343A1 (en) 2015-04-27 2016-11-03 University Of Florida Research Foundation, Incorporated Metabolically programmed metal chelators and uses thereof
GB201604318D0 (en) 2016-03-14 2016-04-27 Avexxin As Combination therapy
US11912676B1 (en) 2023-08-29 2024-02-27 King Faisal University N'-[(4-chlorobenzoyl)oxy]-1,3-benzothiazole-2-carboximidamide as an antitumor and antimicrobial compound
US11919873B1 (en) 2023-08-29 2024-03-05 King Faisal University 1,3-benzothiazol-2-yl-N′-(benzoyloxy)ethanimidamide as an antitumor and antimicrobial compound

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3137655A (en) * 1961-03-21 1964-06-16 Glanzstoff Ag Optical brightening
DE1670908A1 (de) * 1967-08-16 1971-04-29 Hoechst Ag Neue Benzimidazolverbindungen,Verfahren zu ihrer Herstellung und ihre Verwendung als optische Aufhellungsmittel
US3974282A (en) * 1972-11-04 1976-08-10 Beecham Group Limited Hypoglycemic stilbazolte derivatives
DE2331444A1 (de) * 1973-06-20 1975-01-23 Hoechst Ag Neue styryl-benzoxazole, verfahren zu deren herstellung und ihre verwendung als optische aufhellungsmittel
DE3148291A1 (de) * 1981-12-05 1983-06-09 Basf Ag, 6700 Ludwigshafen Harnstoffderivate, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung unerwuenschten pflanzenwuchses
US4594425A (en) * 1984-02-09 1986-06-10 American Home Products Corporation Heterocyclic compounds as antiallergic agents
US4581457A (en) * 1984-09-21 1986-04-08 American Home Products Corporation Heterocyclic sulfonamides

Also Published As

Publication number Publication date
DE3689436D1 (de) 1994-02-03
US4902700A (en) 1990-02-20
DK494186D0 (da) 1986-10-15
JPS62142168A (ja) 1987-06-25
AU6393086A (en) 1987-04-30
EP0219436B1 (en) 1993-12-22
HUT47090A (en) 1989-01-30
DE3689436T2 (de) 1994-04-14
DK494186A (da) 1987-04-17
EP0219436A2 (en) 1987-04-22
AU603343B2 (en) 1990-11-15
HU203228B (en) 1991-06-28
JPH057386B2 (esLanguage) 1993-01-28
UA5585A1 (uk) 1994-12-28
CA1326034C (en) 1994-01-11
EP0219436A3 (en) 1989-12-27
KR870004009A (ko) 1987-05-06
SU1554763A3 (ru) 1990-03-30
KR930006285B1 (ko) 1993-07-12

Similar Documents

Publication Publication Date Title
DK169128B1 (da) Thiazolderivater og farmaceutiske præparater med virkning som leukotrienantagonist indeholdende disse som aktiv bestanddel samt anvendelse af thiazolderivaterne til fremstilling af sådanne præparater
JP6267397B1 (ja) 置換された多環性ピリドン誘導体およびそのプロドラッグを含有する医薬組成物
TWI406856B (zh) 人類免疫缺乏病毒複製之抑制劑
EP2563776B1 (en) Compounds that modulate intracellular calcium
JPH0236159A (ja) 化学化合物類
US20210292283A1 (en) 6-membered heterocyclic derivatives and pharmaceutical composition comprising the same
JPS61200991A (ja) スピロ―３―ヘテロアゾリジン化合物、その製法及びそれを有効成分とする糖尿病合併症の予防及び治療剤
EP1142885B1 (en) 2-(n-cyanoimino)thiazolidin-4-one derivatives
HU203234B (en) Process for producing new, multiply oxygenated labdane derivatives and pharmaceutical compositions comprising such compounds as active ingredient
KR840001614B1 (ko) 4-치환된 피리딘 및 피리미딘 유도체의 제조방법
US20040023928A1 (en) Phosphonate nucleotide and thiadiazole compounds for the treatment of smallpox
JPS6399057A (ja) グリシン誘導体
EP0026000B1 (en) Spiro compounds, process for their preparation and pharmaceutical compositions containing them
EP0005091B1 (fr) Nouvelles pipérazines monosubstituées, leurs procédés de préparation et les compositions pharmaceutiques les renfermant
RU2155765C2 (ru) Производные 1,4-дигидропиридина с циклическим мостиком в положениях 1,2 в форме смеси их изомеров
JP2024528091A (ja) ムスカリン性受容体４アンタゴニストおよび使用方法
EP0000693A1 (de) Aminophenoxymethyl-2-morpholinderivate, ihre Herstellung und sie enthaltende Arzneimittel
EP1098888A1 (fr) Derives de piperazinones et leurs applications
NZ236231A (en) Thio substituted piperidine derivatives and pharmaceutical compositions
KR840001439B1 (ko) 술포네이트 유도체의 제조방법
EP0205872B1 (en) Furobenzisoxazole derivatives
US4761413A (en) 1,5-epoxy-2,3,4,5-tetrahydro-1H-3-benzazepins and use in treatment of ulcers
US4855426A (en) Process of preparing 1,5-epoxy-2,3,4,5-tetrahydro-1H-3-benzazepins
US4910198A (en) 1,5-epoxy-2,3,4,5-tetrahydro-1H-3-benzazepins
KR840000419B1 (ko) 술포네이트 유도체의 제조방법

Legal Events

Date Code Title Description
B1 Patent granted (law 1993)
PBP Patent lapsed